IntraBiotics Pharmaceuticals has discontinued its trial of iseganan for the prevention of ventilator-associated pneumonia

Author：

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1009, 2004-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibiotic prophylaxis strategies in the prevention of ventilator-associated pneumonia

By Sirvent Josep-Maria Torres Antoni

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 8, 2003-08 ,pp. : 1345-1354

Informa Healthcare

Access to resources Recommend Favorite

Diagnosis, Management and Prevention of Ventilator-Associated Pneumonia: An Update

By Vincent Jean-Louis > Cianferoni Silvia

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1927-1944

Adis International

Access to resources Recommend Favorite

Ventilator-associated pneumonia: an overview

By DiCocco Jennifer M Croce Martin A

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 9, 2009-06 ,pp. : 1461-1467

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin in Patients with Early-Onset Ventilator-Associated Pneumonia

By Pea F.

Clinical Pharmacokinetics, Vol. 42, Iss. 6, 2003-01 ,pp. : 589-598

Adis International

Access to resources Recommend Favorite

Antibiotic Resistance of Bacterial Ventilator-associated Pneumonia in Surgical Intensive Care Units

By Namiduru M Güngör G Karaoğlan I Dikensoy Ö

The Journal of International Medical Research, Vol. 32, Iss. 1, 2004-01 ,pp. : 78-83

Field House Publishing

Access to resources Recommend Favorite